These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 19176057)
1. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains]. Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057 [TBL] [Abstract][Full Text] [Related]
2. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608 [TBL] [Abstract][Full Text] [Related]
4. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
5. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
6. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma]. Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054 [TBL] [Abstract][Full Text] [Related]
7. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells]. Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925 [TBL] [Abstract][Full Text] [Related]
8. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. Bishop JD; Nien WL; Dauphinee SM; Too CK J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564 [TBL] [Abstract][Full Text] [Related]
9. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786 [TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658 [TBL] [Abstract][Full Text] [Related]
11. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Slupianek A; Skorski T Exp Hematol; 2004 Dec; 32(12):1265-71. PubMed ID: 15588951 [TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related]
13. Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway. Zhou H; Zhao H; Liu H; Xu X; Dong X; Zhao E J BUON; 2018; 23(6):1732-1738. PubMed ID: 30610801 [TBL] [Abstract][Full Text] [Related]
15. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Li J; Xue L; Hao H; Han Y; Yang J; Luo J Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902 [TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Hansel DE; Platt E; Orloff M; Harwalker J; Sethu S; Hicks JL; De Marzo A; Steinle RE; Hsi ED; Theodorescu D; Ching CB; Eng C Am J Pathol; 2010 Jun; 176(6):3062-72. PubMed ID: 20395440 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]
18. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells. Li H; Kong X; Cui G; Ren C; Fan S; Sun L; Zhang Y; Cao R; Li Y; Zhou J Int J Hematol; 2015 Nov; 102(5):558-68. PubMed ID: 26362858 [TBL] [Abstract][Full Text] [Related]
19. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]